New! View global litigation for patent families

US20170145410A2 - Purification of triphosphorylated oligonucleotides using capture tags - Google Patents

Purification of triphosphorylated oligonucleotides using capture tags Download PDF

Info

Publication number
US20170145410A2
US20170145410A2 US15178881 US201615178881A US2017145410A2 US 20170145410 A2 US20170145410 A2 US 20170145410A2 US 15178881 US15178881 US 15178881 US 201615178881 A US201615178881 A US 201615178881A US 2017145410 A2 US2017145410 A2 US 2017145410A2
Authority
US
Grant status
Application
Patent type
Prior art keywords
capture
oligonucleotide
ppprna
nh
step
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US15178881
Other versions
US20160298116A1 (en )
US9896689B2 (en )
Inventor
Janos Ludwig
Marion Goldeck
Brian Sproat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rheinische Friedrich Wilhelms Universitaet Bonn
Original Assignee
Rheinische Friedrich Wilhelms Universitaet Bonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/02Phosphorylation
    • C07H1/04Introducing polyphosphoric acid radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/02Phosphorylation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/30Production chemically synthesised

Abstract

The present invention relates to a method of preparing triphosphate-modified oligonucleotides using a capture tag. The method allows the synthesis and purification of triphosphate-modified oligonucleotides in high yield and purity suitable for pharmaceutical applications.

Description

  • [0001]
    This application is a divisional of U.S. Ser. No. 14/007,752 filed Sep. 26, 2013, which is a 35 U.S.C. 371 National Phase Entry Application from PCT/EP2012/055520, filed Mar. 28, 2012, which claims the benefit of Europe Patent Application No. 11160032.6 filed on Mar. 28, 2011, the disclosure of which is incorporated herein in its entirety by reference.
  • DESCRIPTION
  • [0002]
    The present invention relates to a method of preparing triphosphate-modified oligonucleotides using a capture tag. The method allows the synthesis and purification of triphosphate-modified oligonucleotides in high yield and purity suitable for pharmaceutical applications.
  • BACKGROUND OF THE INVENTION
  • [0003]
    Schlee et al., Immunity, 2009, 31, 25-34 describe blunt-ended double stranded RNAs carrying a 5′-O-triphosphate moiety on one of the strands that act as potent stimulators of the immune system by binding the RIG-I helicase. Thus, there is a need to provide a simple and efficient method for preparing triphosphate-modified oligonucleotides in high purity, suitable for pharmaceutical applications.
  • [0004]
    The coupling of triphosphate groups or analogues thereof to the 5′-OH group of nucleosidic compounds is well known in the art. Ludwig J. et al., J. Org. Chem., 1989, 54, 631-635 disclose a solution triphosphorylation method for preparing 5′-O-triphosphates of nucleosides and analogues using 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one as the phosphitylating agent. Gaur R. K. et al., 1992, Tetrahedron Letters, 33, 3301-3304 describe the use of said method on solid-phase for the synthesis of 2′-O-methylribonucleoside 5′-O-triphosphates and their Pa-thio analogues. U.S. Pat. No. 6,900,308 B2 discloses the solid-phase synthesis of modified nucleoside 5′-O-triphosphates as potential antiviral compounds and U.S. Pat. Nos. 7,285,658, 7,598,230 and 7,807,653 disclose triphosphate analogues of nucleosides with modifications in the sugar, nucleobase and in the triphosphate entity. WO96/40159 describes a method for producing capped RNA or RNA analogue molecules, wherein an RNA or RNA analogue oligonucleotide is reacted with a phosphitylating agent such as 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one or a ring-substituted derivative thereof. The resulting intermediate is reacted with a phosphate or pyrophosphate or salt thereof, oxidized or hydrolyzed. The di- or triphosphorylated RNA or RNA analogue is capped by reacting with an activated m7G tri-, di- or monophosphate or analogue.
  • [0005]
    WO 2009/060281 describes immune stimulatory oligoribonucleotide analogues containing modified oligophosphate moieties and methods for the preparation of such compounds. This method includes the synthesis of the oligonucleotide on a solid support, reacting a nucleotide at a 5′-end of the oligonucleotide with a phosphitylating agent such as 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one in a suitable solvent and in the presence of a base, reacting the phosphitylated oligonucleotide with a pyrophosphate or pyrophosphate analogue, oxidizing the oligonucleotide with an oxidizing agent and deprotecting the oligonucleotide to give a triphosphate- or triphosphate analogue-modified oligonucleotide.
  • [0006]
    Polyacrylamide gel-electrophoresis as employed in WO 96/40159 is applicable only for small scale separations. The resolution power of ion exchange chromatography for 5′-mono-, di-, triphosphorylated products of longer oligoribonucleotides is limited. The required denaturing conditions make separation a tedious task (Sproat, 1999; Zlatev, 2010; WO 2009/060281), moreover, products are usually contaminated with n−1, n−+2 sequences and their mono- and diphosphates resulting in insufficient purity. Given the sensitivity for precise terminal structures of the RIG-I ligands, these purification methods are suboptimal for pharmacological applications.
  • [0007]
    Dual targeting strategies (siRNA and RIG ligand) require general sequence independent purification methods.
  • SUMMARY OF THE INVENTION
  • [0008]
    It is highly desirable to produce 5′-O-triphosphorylated oligonucleotides and their analogues in large scale for potential clinical use, and a convenient preparation method would be highly desirable. In the present application it is shown that the 5′-O-cyclotriphosphate intermediate of a solid-phase bound fully protected oligonucleotide (see FIG. 1) can be ring opened with a capture tag, e.g. decylamine to give a linear Pγ tagged species that is stable to the deprotection of the RNA. The nature of the tag is such as to impart a specific retention of the capture tagged triphosphate species on a capture tag specific reagent, enabling easy separation from the impurities that do not contain the tag. The tag can be subsequently removed if desired. The method can be extended to encompass analogues of the triphosphate moietity, e.g. analogues containing for instance β,γ-methylene, fluoromethylene, difluoromethylene and imino groups replacing an oxygen atom.
  • [0009]
    Advantages of the capture tagging method are simple purification and improved recovery of the desired species, e.g. at room temperature by RP-HPLC or affinity chromatography, optionally followed by cleavage of the capture tag under suitable conditions.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • [0010]
    The present invention describes the synthesis and purification of oligonucleotide triphosphates, including analogues thereof that contain capture tags. The most widely employed method for the HPLC purification of standard 5′-OH oligonucelotides is reversed phase chromatography of trityl-ON oligonucleotides.
  • [0011]
    The method described in this invention offers a practical solution with similar efficacy for 5′-triphosphorylated oligonucleotides.
  • [0012]
    Thus, a subject-matter of the present invention is a method of preparing an oligonucleotide of formula (I),
  • [0000]
    Figure US20170145410A2-20170525-C00001
      • wherein V1, V3 and V5 are independently in each case selected from O, S and Se;
      • V2, V4 and V6 are independently in each case selected from OH, OR1, SH, SR1, F, NH2, NHR1, N(R1)2 and BH3 M+,
      • W1 is O or S,
      • W2 is O, S, NH or NR2,
      • W3 is O, S, NH, NR2, CH2, CHHal or C(Hal)2,
      • R1, R2 and R3 are selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C2-6 acyl or a cyclic group, each optionally substituted,
      • or wherein two R1 may form a ring together with an N-atom bound thereto,
      • M+ is a cation,
      • X is NH, NR3, O or S,
      • Z represents a capture tag,
      • Y represents a bond or a linker connecting the capture tag to X, and
      • ON represents an oligonucleotide comprising at least 4 nucleotide or nucleotide analogue building blocks, comprising the steps:
  • [0025]
    (a) reacting a compound of formula (IIa)
  • [0000]
    Figure US20170145410A2-20170525-C00002
        • wherein V1, V3, V5, V4, V6, W1, W2, W3, and ON are as defined above, with an oxidizing agent to obtain a compound of formula (IIb)
  • [0000]
    Figure US20170145410A2-20170525-C00003
        • wherein V1, V3, V5, V2, V4, V6, W1, W2, W3 and ON are as defined above,
      • (b) reacting the oxidized compound with a capture tag agent of formula (III),
  • [0000]

    Z—Y—XH  (III)
        • wherein X, Z, and Y are as described above to obtain a reaction product comprising the oligonucleotide of formula (I), and
      • (c) contacting the reaction product of step (b) with a reagent capable of interacting with the capture tag under conditions which allow separation of the oligonucleotide (I) from other species contained in said reaction product.
  • [0031]
    Optionally, the method further comprises the step (d) removing the capture tag to obtain an oligonucleotide of formula (IV),
  • [0000]
    Figure US20170145410A2-20170525-C00004
  • [0000]
    wherein V1, V3, V5, V2, V4, V6, W1, W2, W3 and ON are as described above. This step is carried out under conditions which do not cause degradation of the triphosphate moiety, e.g. as described in detail below.
  • [0032]
    In further embodiments, the capture tag is not or not completely removed. In these embodiments, the tagged oligonucleotide as such may have utility, e.g. utility as pharmaceutical agent.
  • [0033]
    The term “oligonucleotide” in the context of the present application encompasses compounds comprising a plurality, e.g. at least 4 nucleotide or nucleotide analogue building blocks. Preferably, the oligonucleotide comprises 6-100, e.g. 20-40 building blocks. The nucleotide or nucleotide analogue building blocks may comprise nucleoside or nucleoside analogue subunits connected by inter-subunit linkages. The nucleoside subunits include deoxyribonucleoside subunits, ribonucleoside subunits and/or analogues thereof, particularly sugar- and/or nucleobase-modified nucleoside analogues. Further, the oligonucleotides may comprise non-nucleotidic building blocks and/or further terminal and/or side-chain modifications.
  • [0034]
    In preferred sugar-modified subunits the 2′-OH of a ribonucleoside subunit is replaced by a group selected from OR, R, halo, SH, SR, NH2, NHR, NR2 or CN, wherein R is C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl and halo is F, Cl, Br or I. In further preferred sugar-modified subunits, the ribose may be substituted, e.g. by another sugar, for example a pentose such as arabinose. This sugar modification may be combined with 2′-OH modifications as described above, such as in 2′-fluoroarabinonucleoside subunits. Still further preferred sugar-modified subunits include locked nucleosides (LNA) or 2′,3′-seco-nucleosides (UNA). In preferred nucleobase-modified nucleosidic building blocks, a non-standard, e.g. non-naturally occurring nucleobase, is used instead of a standard nucleobase. Examples of non-standard nucleobases are uracils or cytosines modified at the 5-position, e.g. 5-(2-amino)propyl uracil or 5-bromouracil; hypoxanthine; 2,6-diaminopurine; adenines or guanines modified at the 8-position, e.g. 8-bromoguanine; deazanucleosides, e.g. 7-deazaguanine or 7-deazaadenine; or O- and N-alkylated nucleobases, e.g. N6-methyladenine, or N6,N6-dimethyladenine. Further suitable nucleobase analogues may be selected from universal nucleobase analogues such as 5-nitroindole.
  • [0035]
    The inter-subunit linkage between subunits may be a phosphodiester linkage or a modified linkage, e.g. a phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, boranophosphate, or another modified linkage known to a skilled person in the art.
  • [0036]
    The oligonucleotide may be selected from deoxyribonucleotides, ribonucleotides and oligonucleotide analogues. Analogues of desoxyribonucleotides or ribonucleotides may comprise at least one desoxyribonucleoside or ribonucleoside subunit and at least one modified nucleosidic subunit and/or at least one modified inter-subunit linkage, e.g. as described above. Oligonucleotide analogues may also consist in their entirety of modified nucleosidic subunits.
  • [0037]
    The oligonucleotide may be a single-stranded molecule or a double-stranded molecule. Double-stranded oligonucleotides may comprise completely or partially complementary strands. Double-stranded molecules may be blunt-ended or comprise at least one overhang, e.g. a 5′- or 3′-overhang. Overhangs, if present, are preferably located at the distal end of the molecule (with regard to the triphosphate/triphosphate analogue group). Double-stranded oligonucleotides may also comprise a hairpin-structure, wherein the duplex is closed by a loop at the distal end thereof (with regard to the triphosphate/triphosphate analogue group). The loop may comprise nucleotide and/or non-nucleotide building blocks, for example diol-based building blocks such as ethylene glycol moieties, e.g. tri(ethylene)glycol or hexa(ethylene)glycol; propane-1,3-diol; dodecane-1,12-diol; or 3,12-dioxa-7,8-dithiatetradecane-1,14-diol.
  • [0038]
    In a preferred embodiment, double-stranded molecules are blunt-ended, particularly at the proximal end thereof (with regard to the triphosphate/triphosphate analogue group).
  • [0039]
    The oligonucleotide may comprise further terminal and/or side-chain modifications, e.g. cell specific targeting entities covalently attached thereto. Those entities may promote cellular or cell-specific uptake and include, for example lipids, vitamins, hormones, peptides, oligosaccharides and analogues thereof. Targeting entities may e.g. be attached to modified nucleobases or non-nucleotidic building blocks by methods known to the skilled person.
  • [0040]
    The oligonucleotide of formula (I) or (IV) comprises a triphosphate/triphosphate analogue group. In this group, V1, V3 and V5 are independently selected from O, S and Se. Preferably, V1, V3 and V5 are O. V2, V4 and V6 are in each case independently selected from OH, OR1, SH, SR1, F, NH2, NHR1, N(R1)2 and BH3 M+. Preferably, V2, V4 and V6 are OH. R1 may be C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C2-6 acyl or a cyclic group, e.g. a C3-8 cyclo(hetero)alkyl group, a C3-8 cyclo(hetero)alkenyl group, phenyl or C5-6 heteroaryl group, wherein heteroatoms are selected from N, O and S. Further, two R1 may form a ring, e.g. a 5- or 6-membered ring together with an N-atom bound thereto. R1 may also comprise substituents such as halo, e.g. F, Cl, Br or I, O(halo)C1-2 alkyl and—in the case of cyclic groups -(halo)C1-2 alkyl. M+ may be an inorganic or organic cation, e.g. an alkali metal cation or an ammonium or amine cation.
  • [0041]
    W1 may be O or S. Preferably, W1 is O. W2 may be O, S, NH or NR2. Preferably, W2 is O. W3 may be O, S, NH, NR2, CH2, CHHal or C(Hal)2. Preferably, W3 is O, CH2 or CF2. R2 may be selected from groups as described for R1 above. Hal may be F, Cl, Br or I.
  • [0042]
    The triphosphate/triphosphate analogue group is preferably attached to a terminus of the oligonucleotide. Preferably, the group is attached to the 5′-terminus of the oligonucleotide, particularly to the 5′-OH-group of the 5′-terminal sugar thereof.
  • [0043]
    Step (a) of the method of the invention comprises the reaction of cyclic P(V)-P(V)-P(III) species of formula (IIa) with an oxidizing agent. The compound of formula (IIa) may be obtained according to standard methods as described by Ludwig et al, 1989, supra and Gaur et al., 1992, supra, namely by reacting the 5′-terminal OH-group of an oligonucleotide with a trifunctional phosphitylating agent, e.g. 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one under suitable conditions, e.g. in the presence of base (pyridine or diisopropylmethylamine) in a suitable solvent such as dioxane or dichloromethane, and subsequent reaction with pyrophosphate (W3═O) or a modified pyrophosphate (W3 is different from O, e.g. CH2, CCl2, NH or CF2). Preferably, a tri-n-butylammonium salt of the pyrophosphate or modified pyrophosphate in DMF is used. The resulting cyclic P(III)-P(V) intermediate (IIa) is then oxidized under anhydrous conditions, e.g. with a peroxide, such as t-butyl hydroperoxide, cumene hydroperoxide, (10-camphorsulfonyl)oxaziridine. Alternatively, phenylacetyldisulfide (V2═S), or borane-diisopropylethylamine complex (V2═BH3) can also be employed respectively, to give the corresponding cyclic 5′-triphosphate/triphosphate analogue of formula (IIb). Reference in this context is also made to WO 96/40159 or WO 2009/060281, the contents of which are herein incorporated by reference.
  • [0044]
    Reaction step (a) may take place with an oligonucleotide in solution or with an oligonucleotide bound to a solid phase, e.g. an organic resin or glass, such as CPG. The oligonucleotide may further comprise protecting groups, e.g. sugar- or nucleobase protecting groups that are well known to the skilled person. Preferred examples of protecting groups are 2-cyanoethyl for the internucleoside phosphodiester or phosphorothioate, Cert-butyldimethylsilyl, triisopropylsilyloxymethyl or bis(acetoxyethoxy)methyl for the ribose 2′-hydroxyl group, 4-t-butylphenoxyacetyl or phenoxyacetyl, acetyl, isobutyryl, benzoyl for the exocyclic amino groups of the nucleobases. More preferably, step (a) is carried out with a solid-phase bound oligonucleotide.
  • [0045]
    According to step (b) of the method of the invention, compound (IIb) is reacted with a capture tag agent of formula (III)
  • [0000]

    Z—Y—XH  (III)
  • [0000]
    wherein X is a group selected from NH, NR3, O or S. R3 is defined as described above for R1. Preferably, X is NH or S.
  • [0046]
    The capture tag is functionally defined below by a series of plausible Examples. A general rule may be:
  • [0047]
    Z has to allow a convenient purification, and it should be removable under conditions which are compatible with pppRNA stability requirements.
  • [0048]
    Y represents a chemical bond or a linker, e.g. an alkylene, preferably a C1-6-alkylene linker, more preferably a C2-6-alkylene linker, or aralkylene linker, optionally comprising heteroatoms or heteroatom-containing groups, such as O, S, NH, C═O or C═S, and/or optionally comprising C═C or C≡C bonds.
  • [0049]
    In another preferred embodiment the linker is a polyalkylene oxide, preferably a poly-C2-C6-alkylene oxide, more preferably a poly-C2-C3-alkylene oxide. The number average molecular weight of the linker may be in the range from 30-800 g/mol, preferably from 40-450 g/mol, more preferably from 40-250 g/mol. The linker may be [—CH2CHR4—O-]n with n=1-10, preferably n=1-7, more preferably n=2-5, and even more preferably n=3. R4 may be H or C1-6-alkyl.
  • [0050]
    In a preferred embodiment R4 is H.
  • [0051]
    In an especially preferred embodiment the linker has the formula —CH2—CH2—[(O—CH2CH2)]3—.
  • [0052]
    Reaction step (b) may take place with an oligonucleotide in solution or with an oligonucleotide bound to a solid phase, e.g. an organic resin or glass. The oligonucleotide may further comprise protecting groups as described above. More preferably, step (b) is carried out with a solid phase-bound oligonucleotide.
  • [0053]
    The capture tag Z according to the present invention is a moiety capable of non-covalently or covalently interacting with a capture reagent under conditions which allow separation for compounds comprising the capture tag, e.g. the oligonucleotide (I) from other species, which do not contain the capture tag. Preferably, the capture reagent is an immobilized reagent or a reagent capable of being immobilized.
  • [0054]
    Suitable capture tags are for instance long-chain, e.g. C8-24, preferably C13-24 aliphatic alkyl residues such as decyl or octadecyl or other lipidic/lipophilic residues such as e.g. cholesteryl or tocopheryl. In this case, the tagged triphosphate entity can be captured and purified on a solid phase by standard reversed phase chromatography, e.g. RP-HPLC, or by hydrophobic interaction chromatography (HIC). The capture tag may also be a perfluoroalkyl entity, e.g. a 4-(1H,1H,2H,2H-perfluorodecyl)benzyl or a 3-(perfluorooctyl)propyl residue for specific capture of the modified oligo-triphosphate on a Fluorous Affinity support such as is commercially available from Fluorous Technologies, Inc.
  • [0055]
    In another embodiment, the capture tag may be a first partner of a non-covalent high-affinity binding pair, such as biotin, or a biotin analogue such as desthiobiotin, a hapten or an antigen, which has a high affinity (e.g. binding constant of 10−6 l/mol or less) with the capture reagent, which is a second complementary partner of the high-affinity binding pair, e.g. a streptavidin, an avidin or an antibody.
  • [0056]
    In yet another embodiment, the capture tag may be a first partner of a covalent binding pair, which may form a covalent bond with the capture reagent, which is a second complementary partner of the covalent binding pair, wherein the covalent bond may be a reversible or an irreversible bond. In this embodiment, the capture tag component Z may be a reactive chemical entity such as an azide or alkynyl group enabling covalent reaction with a capture reagent that contains a complementary reactive group, e.g. an alkynyl or azido moiety, respectively, in the case of the Husigen 3+2 cycloaddition reaction (the so-called “click-reaction” that is Cu(I) catalyzed or a variant thereof that proceeds without Cu(I) ions via release of severe ring strain in e.g. cyclooctyne derivatives). A specific example for Z—Y—X in such a case would be propargylamino.
  • [0057]
    In another embodiment, the capture tag component may be a chemical entity which contains an additional nucleophilic group, for instance a second amino group in an NH2—Y—XH type reagent. A wide range of suitable electrophilic Z reagent such as cholesterol, chloroformiate or biotin N-hydroxy succinimide active esters may then be used to introduce the tagging group while the oligonucleotide is attached to the solid phase, thus significantly extending the scope of the tagging reaction.
  • [0058]
    In a preferred embodiment the capture tag is a long-chain alkyl residue, a perfluoroalkyl entity, an azide or an alkynyl group.
  • [0059]
    Moreover, Y may optionally contain a disulfide bond to enable recovery of the modified triphosphorylated oligonucleotide with a free sulfhydryl moiety connected via part of the linker through X to the γ-phosphorus.
  • [0060]
    In a further embodiment of the present invention, the oligonucleotide may carry a second capture tag at a different position, e.g. at the 3′-terminus. The first and the second capture tags are preferably selected as to allow purification by two orthogonal methods to enable recovery of extremely high purity material. For example the first capture tag may be a lipophilic group, which interacts with a suitable chromatographic support and the second capture tag may be biotin, which interacts with streptavidin.
  • [0061]
    The second capture tag may be conveniently introduced by performing the synthesis using a modified CPG (controlled glass support) for oligoribonucleotide synthesis.
  • [0062]
    Step (c) of the method of the present invention comprises contacting the reaction product of step (b), with a capture reagent capable of interacting with the capture tag Z under conditions which allow separation of the capture tag containing oligonucleotide (I) from other species contained in the reaction product. Before step (c), the solid phase bound oligonucleotide (I) is cleaved from the solid phase and deprotected, i.e. the protection groups are partially or completely removed. The capture reagent is preferably immobilized on a suitable support, e.g. a chromatographic support. In order to provide separation of capture tag containing oligonucleotide (I) from non-capture tag-containing species, the reaction products from step (b) are cleaved from a solid phase and deprotected, if necessary, and subjected to a separation procedure, preferably a chromatographic separation procedure based on the interaction of the capture tag Z with the capture reagent. During the separation step, the purity of the oligonucleotide (I), which is generally in the range of 25-70% for the crude material depending upon the length and complexity of the sequence, may be increased to 90%, 91%, 92%, 93%, 94%, 95% or more. For toxicity studies a purity of >85% is desirable, whereas in late stage clinical trials the purity should be in the range of at least 90-95%. Thus, the present invention provides a way to obtain a high purity pppRNA as would be required for human clinical trials.
  • [0063]
    In step (c), the capture tag and the capture reagent capable of interacting therewith are preferably selected from (i) a hydrophobic or fluorinated group and a chromatographic material with affinity for hydrophobic or fluorinated groups, e.g. a reversed phase material or a fluorous affinity support; (ii) a first partner of a non-covalent high-affinity binding pair and a second complementary partner of a non-covalent high-affinity binding pair, (iii) a first partner of a covalent binding pair and a second complementary partner of a covalent binding pair, where the first and second partner form covalent bonds.
  • [0064]
    After the purification step (c), capture tag Z may be cleaved from the triphosphate-modified oligonucleotide in a further step (d) resulting in an untagged oligonucleotide (IV).
  • [0065]
    Step (d) has to be compatible with stability requirements of the triphosphate end product and with stability requirements of the interribonucleotide bond. It may comprise cleavage by mildly acidic conditions when X is NH, cleavage with silver ions when X is S, cleavage by a thiol such as dithiothreitol leading to elimination of thiirane when Y—X—P contains —S—S—CH2—CH2—O—P.
  • [0066]
    In further embodiments, the capture tag set remains completely or partially on the triphosphate-modified oligonucleotide, particularly when the tagged oligonucleotide is suitable for pharmaceutical applications. In these embodiments, the reagent Z—Y—XH has to be selected from a subgroup of Z-residues, which are functionally compatible with the structural requirements of the RIG-I sensor. For instance, the Z=decyl-octadecyl, Y=link XH═NH combination is known to fulfill these requirements.
  • [0067]
    The triphosphate/triphosphate analogue modified oligonucleotides produced according to the present invention are particularly suitable for pharmaceutical applications due to their high purity. In an especially preferred embodiment, the oligonucleotide (I) or (IV) is an activator of RIG-1 helicase. Specific examples of suitable RIG-1 activators are disclosed in Schlee et al., 2009, supra, the content of which is herein incorporated by reference.
  • [0068]
    In another embodiment the present invention refers to oligonucleotides of Formula (I), obtainable by a method according to the present invention.
  • [0069]
    Still another subject-matter of the invention is the use of a kit for preparing an oligonucleotide of formula (I)
  • [0000]
    Figure US20170145410A2-20170525-C00005
  • [0000]
    wherein V1, V3, V5, V2, V4, V6, W1, W2, W3, X, Y, Z and ON are defined as above,
    wherein the kit comprises (a) a capture tag agent of formula (III)
  • [0000]

    Z—Y—XH  (III)
  • [0000]
    wherein X, Z and Y are defined as above, and
    (b) a capture reagent capable of interacting with the capture tag.
  • [0070]
    Still another subject-matter of the invention is a modified oligonucelotide of formula (I)
  • [0000]
    Figure US20170145410A2-20170525-C00006
  • [0000]
    wherein
    X is NH, O, R—O—[P(V1)V2—W1]n or R—O—P(V3)V4—W2—P—(V1)V2—W1,
    n is 1-12, preferably 1 or 2,
    Y is a bond,
    Z is C13-C24 alkyl, Q or QNHC2-C24 alkyl,
    Q is selected from H, aminoacids, aminoacid analogues, C1-C24 alkyl, preferably C12-C24 alkyl, peptides and lipids,
    R is C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl and lipids,
    R is C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C2-C24 acyl or a cyclic group, and optionally substituted,
    and V1, V2, V3, V4, V5, V6, W1, W2, W3 and ON are defined as in any one of claims 1-11, wherein V1, V2, V3, V4, V5, V6, W1, W2 and W3 are preferably O.
  • [0071]
    According to a preferred embodiment of the present invention a modified oligonucleotide of formula (I) has X being NH. This embodiment preferably has Z being Q or Z being QNHC2-C24 alkyl, wherein in a particularly preferred embodiment C2-C24 alkyl is C2 alkyl and/or Q is H. Particularly preferred embodiments of the identified oligonucleotide according to the invention are shown in FIG. 8.
  • [0072]
    Further, the present invention shall be explained in more detail by the following Figures and Examples.
  • [0073]
    FIG. 1 shows a schematic overview of the method of the invention using a decyl residue as capture tag Z
  • [0074]
    FIGS. 2A-C shows RP-HPLC purification of pppRNA via n-decyl-NH-pppRNA intermediate
  • [0000]
    (A) crude reaction mixture containing 65% n-decyl-NH-pppRNA (peak at 14 min);
    (B) isolated n-decyl-NH-pppRNA;
    (C) pppRNA; the pH=3.8 60 min hydrolysis product from B
  • [0075]
    In FIG. 2 the x-axis means time [min] and the y-axis means absorbance at 260 nm [mAu].
  • [0076]
    The broad peak at 10 min retention time in A contains the nonphosphory-lated 24-mer, shorter synthesis failure sequences, the minor pppRNA hydrolysis product and the 5′-H-phosphonate derivative of the 24-mer. The insert shows the position of pppRNA and 5′-OH RNA in this system.
  • [0077]
    Column: Hamilton PRP-1 4.1×250 mm, 10 μm
  • [0078]
    Gradient: 1-100% B in 18 min, A=0.05 M TEAB; B=80% Methanol 0.05 M TEAB
  • [0079]
    FIGS. 3A-C shows MALDI-TOF spectra (x-axis: mass [Da]) corresponding to HPLC traces A, B and C in FIG. 2 respectively.
  • [0080]
    (A) spectrum recorded from the crude reaction mixture after desalting showing the presence of n-decyl-NH-ppp RNA (24d), pppRNA (24c), 5′-H-phosphonate RNA(24b) and 5′-OH -RNA(24a) and shorter synthesis failure sequences indicated as peaks 12-23;
  • [0081]
    (B) spectrum recorded from HPLC isolated n-decyl-NHpppRNA (B),
  • [0082]
    (C) spectrum of pure pppRNA as obtained from the direct EtOH precipitation of the pH=3.8 hydrolysis product of n-decyl-NH-pppRNA
  • [0083]
    FIGS. 4A-B shows a reaction scheme explaining the generation of side products 24 a-c
  • [0084]
    FIG. 5 shows the time course for the conversion of n-decyl-NH-pppRNA to pppRNA via acidic hydrolysis of the phosphoramidate bond.
  • [0085]
    FIGS. 6A-C shows typical MALDI spectra (x-axis: mass [Da]) of 21-mer, 24-mer, 27-mer pppRNA products as obtained after capture tag removal and EtOH precipitation as Na+ salt. The correct mass peak is observed at m/z 6911.6 (A), m/z 7828 (B), m/z 8808.1 (C) and the peaks at m/z 3462 (A), m/z 3918 (B), 4408 (C) are due to the doubly charged pppRNA, respectively. Similar quality spectra have been obtained in more than 50 examples with a variety of sequences containing nucleoside analogs and 3′ modifications in the 15-42-mer range.
  • [0086]
    FIG. 7A shows a semipreparative scale reversed phase HPLC purification of a 1 μmol scale reaction of decyl-NHpppRNA 21 mer on a 7 mm Hamilton PRP-1 column
  • [0087]
    Column: Hamilton PRP-1 7×250 mm, 10 μm Flow rate 3 mL/min.
  • [0088]
    Gradient: 1-80% B in 50 min, A=0.1M TEAB; B=80% Methanol 0.1 M TEAB
  • [0089]
    FIG. 7B and FIG. 7C show semipreparative scale reversed phase HPLC purifications, in particular showing how the inventive method is able to deal with sub-optimal synthesis and/or 5′-phosphorylation conditions.
  • [0090]
    In all figures the x-axis is volume [ml] and the y-axis is absorbance at 260 nm [mAu].
  • [0091]
    FIG. 8 shows especially preferred modified oligonucleotides of formula (I).
  • [0092]
    FIGS. 9A-B shows the synthesis of compounds F-TAG-pppRNA and N3-TAG-pppRNA (A) and the strategy for reversible covalent immobilisation using N3-TAG RNA (B)
  • [0093]
    FIGS. 10A-B shows MALDI spectra of F-TAG-pppRNA (A) N3-TAG-pppRNA (B)
  • [0094]
    FIG. 11 shows the RP-HPLC analysis of pppRNA and n-alkyl-NH-pppRNAs with alkyl residues of increasing chain length:
      • A. pppRNA, RT=9.3 min
      • B. n-decyl-NH-pppRNA, RT=13.8 min,
      • C. n-dodecyl-NH-pppRNA, RT=15.5 min
      • D. n-tetradecyl-NH-pppRNA, RT=17.3 min
      • E. n-octadecyl-NH-pppRNA, RT=19.7 min
    EXAMPLE 1 Preparation of a 5′-Triphosphate Modified Oligonucleotide Using a Decyl Amine Capture Tag Purification Step
  • [0100]
    An overview of the reaction scheme described in Example 1 is shown in FIG. 1.
  • [0101]
    Step 1:
  • [0102]
    Dissolve 203 mg (1 mmol) of 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one in 1 mL of dry dioxane in a 10 mL septum vial under argon.
  • [0103]
    Step 2:
  • [0104]
    Dry the synthesis column containing the fully protected RNA that has been detitrylated and thoroughly washed with acetonitrile, in vacuum for 12 h. Wash the column contents thoroughly by repeatedly drawing in and expelling 2 mL of anhydrous dioxane/pyridine solution, 3:1 (v/v) in an argon atmosphere.
  • [0105]
    Step 3:
  • [0106]
    Add into a vial first 2 mL of pyridine/dioxane, 3:1 v/v followed by 100 μL of 1 M 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one solution in dry dioxane to give a 50 mM solution of the phosphitylating reagent, e.g. 2-chloro-4H-1,3,2-benzodioxaphosphorin-2-one, in dioxane/pyridine, 3:1 (v/v). Homogenize the solution by gently shaking. Start the reaction by drawing the 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one solution through the synthesis column from the vial.
  • [0107]
    During the reaction, repeatedly draw in and expel the 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one containing solution from the synthesis column, in order to allow thorough contact and good mixing with the solid phase supported RNA. A 30 min reaction time usually gives near quantitative reaction of the free 5′-OH group of the support bound oligomer in the 20-40 nt range.
  • [0108]
    Step 4:
  • [0109]
    After a 30 min reaction time expel the dioxane/pyridine solution containing the excess phosphitylating agent into a waste container, fill a new syringe with a vortexed mixture of 1 mL of 0.5 M (Bu3NH)2 pyrophosphate in dry DMF and 238 μL (1 mmol) of dry Bu3N to give a 0.5 M (Bu3N)4 pyrophosphate solution. Push this solution through the column thereby replacing the dioxane/pyridine solution. The large excess of the pyrophosphate ensures a quantitative conversion of the intermediate to the P(III)-P(V) cyclic anhydride IIa.
  • [0110]
    Step 5:
  • [0111]
    Wash the column with 3 mL of CH3CN to remove the DMF and excess PPi, and to fill the column reactor with dry CH3CN.
  • [0112]
    Step 6:
  • [0113]
    Dissolve 300 μL of t-BuOOH (5.5 M solution in decane, Sigma-Aldrich) in 2 mL of anhydrous CH3CN to give an approximately 0.7 M homogeneous solution. Contact the synthesis support with this solution for 15 min in order to obtain the oxidized P(V) cyclic anhydride IIb.
  • [0114]
    Step 7:
  • [0115]
    Wash the column with 3 mL of dry CH3CN to remove the excess peroxide and fill it with dry CH3CN.
  • [0116]
    Step 8:
  • [0117]
    Dissolve 300 μL of dry decylamine in 1 mL of dry CH3CN under argon and bring the solution in contact with the support in the column. Move the decylamine solution through the support. The contact time of the CPG with the amine solution should be 3 min.
  • [0118]
    Step 9: Wash the column thoroughly with 9 mL acetonitrile, then dry the column contents by flushing argon through it.
  • [0119]
    Step 10—First Stage of the Deprotection:
  • [0120]
    Pass 1 mL of deprotection solution (40% aq. methylamine/conc. aq. ammonia 1:1 v/v. AMA reagent) through the support for 2-3 times. After a contact of 30 min transfer the solution into a new vial. Wash the support with same volume of AMA deprotection solution and combine the washings. Heat the combined solution and washings for 10 min at 65° C. After cooling on ice, concentrate the solution to a volume of 300-500 μL, then evaporate to dryness.
  • [0121]
    Step 11—Removal of the 2′-O-TBDMS Protecting Groups:
  • [0122]
    Dry the residue by addition and coevaporation of 300 μL of dry EtOH, add 1 mL of dry 1 M TBAF (tetra-n-butylammonium fluoride) in THF, seal tightly and put on a shaker for 16 h. Quench the reaction with 1 mL of sterile aqueous 1 M TEAB (triethylammonium bicarbonate), and desalt it on a NAP™-25 (Nucleic Acid Purification) column using sterile water as eluent. Filtration through a sterile 2 μm filter may be necessary at this step. Combine and evaporate the UV-absorbing fractions to a volume of 150 μL, add 100 mL of 1 M TEAB pH8 and store the solution frozen at −20° C. until the HPLC purification can be performed. The decyl-NHpppRNA product is stable at −20° C. for weeks at pH 7-8.
  • [0123]
    Step 12—HPLC Purification:
  • [0124]
    The reaction product from an 1 μmol scale reaction mixture from step 11 was loaded into a 7×25 mm PRP-1 column (Hamilton). Purification was performed using a linear gradient buffer B from 0 to 80% in 50 min at a flow rate of 3 mL/min. Buffer A is 100 mM TEAB and buffer B is 100 mM TEAB in methanol/water 8:2 v/v. A typical example of a 27-mer purification is shown in FIG. 7A.
  • [0125]
    Fractions 5 and 6 are collected, evaporated on a rotary evaporator and desalted by several coevaporations with dry methanol, The residue (approx. 200-250 nmol of decyl-NHpppRNA) was dissolved in water and transferred into a screw cap Eppendorf vial.
  • [0126]
    Step 13—Removal of the Decylamine Tag:
  • [0127]
    100 nmol of decyl-NHpppRNA was dissolved in 400 μL of pH 3.8 deprotection buffer in a 2 mL Eppendorf tube, and the sealed tube was heated at 60° C. for 70 min. These conditions result in quantitative cleavage of the phosphoramidate bond with no degradation of the triphosphate moiety. Then the reaction mixture was cooled on ice and 25 μIof sterile 5 M NaCl solution and 1.2 mL of absolute EtOH were added. After thorough mixing the solution was kept at −20° C. overnight to precipitate the pppRNA. The precipitate was collected by centrifugation, washed with cold ethanol, dried on a SpeedVac, then dissolved in 500 mL of sterile water and stored frozen at −20° C.
  • [0000]
    TABLE 1
    Summary of the reaction conditions for introduction
    of the 5′-terminal decyl-NHppp-residue.
    Step Reagent Time
    1 3 mL dioxane/pyridine, 3:1 v/v wash
    2 50 mM 2-chloro-4H-1,3,2-benzodioxaphosphorin- 30 min ←→
    4-one in 2 mL of dioxane/pyridine, 3:1 v/v
    3 1 mL of 0.5M (Bu3NH)2PPi in DMF plus 10 min ←→
    238 μL of Bu3N
    4 3 mL of dry acetonitrile wash
    5 300 μL of t-BuOOH (5.5M in decane) in 2 mL of 15 min ←→
    CH3CN
    6 3 mL of dry acetonitrile Wash
    7 300 μL of n-decylamine in 1 mL of dry  3 min ←→
    acetonitrile (1.1M decylamine)
    8 10 mL of acetonitrile wash
    1 μmol scale synthesis column containing support bound detitrylated RNA
    Figure US20170145410A2-20170525-P00001
     bidirectional movements of reagents,
    → unidirectional washing step
  • [0128]
    In analogous manner, a 5′-triphosphate modified oligonucleotide was also synthesized and purified using an octadecyl or a cholesteryl capture tag.
  • EXAMPLE 2 Preparation of Triphosphate Oligonucleotides Using Non-Lipophilic Capture Tags (F-TAG-pppRNA and N3-TAG-pppRNA)
  • [0129]
    In order to demonstrate the utility of non-lipophilic interaction based purification strategies the pppRNA derivatives F-TAG-RNA and N3-TAG-RNA were prepared (see FIG. 9). All steps of the synthesis are identical with the procedure described in Example 1 except that in step 8 of FIG. 1, 2 mL of a 0.1 M solution of 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-Heptadecafluoroundecylamine in anhydrous acetonitrile was used for the ring opening of the solid phase bound cyclotriphosphate with an increased 3 h reaction time to give F-TAG-RNA; and 2 mL of a 0.1 M solution of 11-azido-3,6,9-trioxaundecan-1-amine in dry acetonitrile for 3 h was used to give N3-TAG-pppRNA. The following deprotection steps are identical with those given in the detailed description for DecNHpppRNA in Example 1.
  • F-TAG-RNA and N3-TAG-RNA Analytical Data (See FIG. 10):
  • [0130]
  • [0000]
    (the RNA sequence in these examples is
    5′-GACGCUGACCCUGAAGUUCAUCUU)
    Time
    required
    for
    complete
    P-N
    Calcu- Mass cleavage
    HPLC lated measured at pH
    retention Mass, by 3.8 at
    time* Da MALDI, Da 60° C.
    F-TAG-pppRNA 15.1 min 8287.74 8290.30 70 min
    N3-TAG-ppRNA   11 min 8033.20 8033.92 70 min
    * PRP-1 column 0-100% B in 20 min (A = 100 mM Triethylammoniumbicarbonate (TEAB),
    B = 100 mM TEAB 80% MeOH)
  • [0131]
    pppRNA oligonucleotides containing fluorous tags (F-TAG-pppRNA) can be purified using commercial “fluorous” cartridges, or fluorous HPLC columns which enable the exploitation of the strong nonconvalent interaction between perfluorinated alkyl chains. The gamma azide modified pppRNA derivatives (N3-TAG-pppRNA) can be covalently bound to commercially available propyne modified solid phases by RNA compatible versions of the copper(I)-catalysed-alkyne-azide cycloaddition reaction (click chemistry). This procedure enables the purification of highly structured pppRNA sequences because in the resin bound form denaturing conditions can be applied to remove non-triphosphorylated by-products.
  • [0132]
    Upon acid hydrolysis both F-TAG-RNA and N3-TAG-RNA release the pppRNA end product with comparable kinetics to the simple P—N alkyl amide as described in FIG. 5.
  • EXAMPLE 3 Variation of the RP-HPLC Elution Position of Tag-pppRNA by n-Alkyl Capture Tags of Increasing Chain Length
  • [0133]
    Besides the n-decyl-tag described in Example 1, aliphatic n-alkyl residues with longer chain lengths (C12, C14, C18) can be used to increase the retention time of the Tag-pppRNA product during RP-HPLC purification enabling an efficient separation from impurities that do not contain the tag. N-dodecyl-NH-pppRNA, n-tetradecyl-NH-pppRNA and n-octadecyl-NH-pppRNA can be prepared following the procedure described in example 1 by variation of step 8: A 0.1 M solution of n-alkylamine (n-dodecylamine, n-tetradecylamine or n-octadecylamine) in dry CH2Cl2 is prepared and 2 mL of the solution is brought in contact with the support in the column. The alkylamine solution is pushed to and fro through the support. After a contact time of 3 h an additional washing step with 2 mL of CH2Cl2 is required prior to continuing with the next workup steps.
  • Analytical Data:
  • [0134]
  • [0000]
    RP-HPLC* Mass Time for
    retention Calculated measured by complete P-N
    time Mass MALDI cleavage at
    (min) (Da) (Da) pH 3.8 at 60° C.
    C12—NH- 15.5 7995.7 7999.2 70 min
    pppRNA
    C14—NH- 17.3 8023.7 8028.1 70 min
    pppRNA
    C18—NH- 19.7 8079.8 8082.2 70 min gives >
    pppRNA 80% product
    *PRP-1 column 0-100% B in 20 min (A = 100 mM Triethylammoniumbicarbonate, B = 100 mM TEAB 80% MeOH)
  • [0135]
    FIG. 11 shows the RP-HPLC analysis of pppRNA and n-alkyl-NH-pppRNAs with alkyl residues of increasing chain length.

Claims (20)

  1. 1-15. (canceled)
  2. 16. A method of preparing an oligonucleotide of formula (I),
    Figure US20170145410A2-20170525-C00007
    wherein V1, V3 and V5 are independently selected from the group consisting of O, S and Se;
    V2, V4 and V6 are independently selected from the group consisting of OH, OR1, SH, SR1, F, NH2, NHR1, N(R1)2 and BH3 M+,
    W1 is O or S,
    W2 is O, S, NH or NR2,
    W3 is O, S, NH, NR2, CH2, CHHal or C(Hal)2,
    R1, R2 and R3 are selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C2-6 acyl and a cyclic group, each substituted or unsubstituted,
    or wherein two R1 may form a ring together with an N-atom bound thereto,
    M+ is a cation,
    X is NH, NR3, O or S,
    Z represents a capture tag which is a long-chain alkyl residue, a perfluoroalkyl entity, an azide, an alkynyl group, a chemical entity containing a second amino group in an NH2—Y—XH type reagent, a chloroformate group, a lipidic residue, or a first partner of a non-covalent binding pair which has a binding constant of 10−6 l/mol or less to its complementary binding partner,
    Y represents a bond or a linker connecting the capture tag to X, and
    ON represents an oligonucleotide comprising at least 4 nucleotides or nucleotide analogue building blocks,
    comprising the steps:
    (a) reacting a compound of formula (IIa)
    Figure US20170145410A2-20170525-C00008
    with an oxidizing agent to obtain a compound of formula (IIb)
    Figure US20170145410A2-20170525-C00009
    (b) reacting a compound of formula (IIb) with a capture tag agent of formula (III),

    Z—Y—XH  (III)
    to obtain a reaction product comprising the oligonucleotide of formula (I), and
    (c) contacting the reaction product of step (b) with a capture reagent capable of interacting with the capture tag, wherein the contacting takes place under conditions which allow separation of the oligonucleotide (I) from other species contained in said reaction product.
  3. 17. The method of claim 16, wherein Y is an alkylene linker, or an aralkylene linker selected from the group consisting of
    (i) an alkylene linker, or an aralkylene linker comprising heteroatoms or heteroatom containing groups,
    (ii) an alkylene linker, or an aralkylene linker comprising C═C or C≡C bonds, and
    (iii) an alkylene linker, or an aralkylene linker comprising both heteroatoms or heteroatom containing groups, and C═C or C≡C bonds.
  4. 18. The method of claim 17, wherein the heteroatom containing groups are selected from the group consisting of O, S, NH, C═O, and C═S.
  5. 19. The method of claim 16, wherein Y is a polyalkylene oxide linker selected from
    (i) a poly-C2-C6-alkylene oxide,
    (ii) a poly-C2-C3-alkylene oxide,
    (iii) a linker with a number average molecular weight in the range of 30-800 g/mol, and
    (iv) a linker which is [—CH2CHR4—O-]n, wherein n is 1-10, and R4 represents H or C1-6-alkyl.
  6. 20. The method of claim 16, wherein Y is —CH2—CH2—[(O—CH2CH2)]3—.
  7. 21. The method of claim 16, wherein Z is a lipidic residue selected from cholesteryl and tocopheryl.
  8. 22. The method of claim 16, wherein Z is a perfluoralkyl entity selected from a 4-(1H,1H,2H,2H-perfluorodecyl)benzyl and 3-(perfluorooctyl)propyl residue.
  9. 23. The method of claim 16, wherein Z is a first partner of a non-covalent binding pair selected from biotin, desthiobiotin, a hapten, and an antigen, and the complementary binding partner is a streptavidin, an avidin, or an antibody.
  10. 24. The method of claim 16, wherein Z—Y—X is propargylamino.
  11. 25. The method of claim 16, wherein the capture tag and the capture reagent capable of interacting therewith are selected from:
    (i) a hydrophobic or fluorinated group and a chromatographic material with affinity for hydrophobic or fluorinated groups;
    (ii) a first partner of a non-covalent binding pair and a second partner of a non-covalent binding pair, and
    (iii) a first partner of a covalent binding pair and a second partner of a covalent binding pair, where the first and second partner form covalent bonds.
  12. 26. The method of claim 16,
    wherein the triphosphate/triphosphate analogue group is attached to the 5′-terminus of the oligonucleotide.
  13. 27. The method of claim 26, wherein the triphosphate/triphosphate analogue group is attached to the 5′-OH-group of the 5′-terminal sugar thereof.
  14. 28. The method of claim 16, further comprising the step:
    (d) removing the capture tag to obtain an oligonucleotide of formula (IV):
    Figure US20170145410A2-20170525-C00010
    wherein V1, V3, V5, V2, V4, V6, W1, W2, W3 and ON are as defined in claim 16.
  15. 29. The method of claim 16, wherein the oligonucleotide is selected from desoxyribonucleotides, ribonucleotides and oligonucleotide analogues.
  16. 30. The method of claim 16, wherein the oligonucleotide is single-stranded or double stranded.
  17. 31. The method of claim 30, wherein the oligonucleotide is double-stranded and the duplex is closed by a loop at the distal end thereof, wherein the loop comprises nucleotide and/or non-nucleotide building blocks.
  18. 32. The method of claim 30, wherein the oligonucleotide is double-stranded and the duplex is blunt-ended at the proximal end thereof.
  19. 33. Oligonucleotide of Formula (I), obtainable by a method comprising
    (a) reacting a compound of formula (IIa)
    Figure US20170145410A2-20170525-C00011
    with an oxidizing agent to obtain a compound of formula (IIb)
    Figure US20170145410A2-20170525-C00012
    (b) reacting a compound of formula (IIb) with a capture tag agent of formula (III),

    Z—Y—XH  (III)
    to obtain a reaction product comprising the oligonucleotide of formula (I), and
    (c) contacting the reaction product of step (b) with a capture reagent capable of interacting with the capture tag, wherein the contacting takes place under conditions which allow separation of the oligonucleotide (I) from other species contained in said reaction product,
    wherein V1, V3, V5, V2, V4, V6, W1, W2, W3, X, Y, Z and ON are defined as in claim 16, and wherein X, Z and Y are defined as in claim 16.
  20. 34. A kit for preparing an oligonucleotide of formula (I)
    Figure US20170145410A2-20170525-C00013
    wherein V1, V3, V5, V2, V4, V6, W1, W2, W3, X, Y, Z and ON are defined in claim 16, wherein the kit comprises:
    (a) a capture tag agent of formula (III)

    Z—Y—XH  (III)
    wherein X, Z and Y are defined as in claim 16, and
    (b) a capture reagent capable of interacting with the capture tag.
US15178881 2011-03-28 2016-06-10 Purification of triphosphorylated oligonucleotides using capture tags Active US9896689B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP20110160032 EP2508530A1 (en) 2011-03-28 2011-03-28 Purification of triphosphorylated oligonucleotides using capture tags
EP11160032 2011-03-28
EP11160032.6 2011-03-28
PCT/EP2012/055520 WO2012130886A1 (en) 2011-03-28 2012-03-28 Purification of triphosphorylated oligonucleotides using capture tags
US201314007752 true 2013-09-26 2013-09-26
US15178881 US9896689B2 (en) 2011-03-28 2016-06-10 Purification of triphosphorylated oligonucleotides using capture tags

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15178881 US9896689B2 (en) 2011-03-28 2016-06-10 Purification of triphosphorylated oligonucleotides using capture tags

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US14007752 Division US9399658B2 (en) 2011-03-28 2012-03-28 Purification of triphosphorylated oligonucleotides using capture tags
PCT/EP2012/055520 Division WO2012130886A1 (en) 2011-03-28 2012-03-28 Purification of triphosphorylated oligonucleotides using capture tags
US201314007752 Division 2013-09-26 2013-09-26

Publications (3)

Publication Number Publication Date
US20160298116A1 true US20160298116A1 (en) 2016-10-13
US20170145410A2 true true US20170145410A2 (en) 2017-05-25
US9896689B2 US9896689B2 (en) 2018-02-20

Family

ID=44453820

Family Applications (2)

Application Number Title Priority Date Filing Date
US14007752 Active US9399658B2 (en) 2011-03-28 2012-03-28 Purification of triphosphorylated oligonucleotides using capture tags
US15178881 Active US9896689B2 (en) 2011-03-28 2016-06-10 Purification of triphosphorylated oligonucleotides using capture tags

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14007752 Active US9399658B2 (en) 2011-03-28 2012-03-28 Purification of triphosphorylated oligonucleotides using capture tags

Country Status (8)

Country Link
US (2) US9399658B2 (en)
EP (3) EP2508530A1 (en)
JP (2) JP5981985B2 (en)
CN (2) CN103492405B (en)
CA (1) CA2830980A1 (en)
DK (1) DK2691410T3 (en)
ES (1) ES2623002T3 (en)
WO (1) WO2012130886A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100178272A1 (en) 2006-08-08 2010-07-15 Klinische Pharmakologie Structure and use of 5'phosphate oligonucleotides
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) * 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
DE102015008536A1 (en) 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Discontinuous oligonucleotide ligands

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3534017A (en) 1967-03-14 1970-10-13 Kyowa Hakko Kogyo Kk Process for the preparation of nucleoside-5'-diphosphates and triphosphates and mono- and oligo-nucleotidyl-nucleoside-5'-diphosphates and triphosphates
US4210746A (en) 1978-08-10 1980-07-01 National Research Development Corporation Nucleotide inhibitor of protein synthesis
US4285605A (en) 1979-07-02 1981-08-25 International Business Machines Corporation Escapement mechanism and backspace mechanism for a moving paper carriage typewriter having dual pitch capability
FR2471785B1 (en) 1979-12-21 1982-11-05 Fabre Sa Pierre
DE3023787A1 (en) 1980-06-25 1982-01-21 Studiengesellschaft Kohle Mbh A method for increasing the incorporation and expression of genetic material into the nuclei of intact cells using liposome-
EP0081099A3 (en) 1981-12-04 1983-08-10 Sloan-Kettering Institute For Cancer Research Capped oligonucleotide anti-viral agents
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5194428A (en) 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
DE68925278T2 (en) 1988-02-26 1996-09-19 Worcester Found Ex Biology Inhibition of HTLV-III by exogenous oligonucleotides
DE68929305D1 (en) 1988-04-27 2001-07-19 Isis Pharmaceutical Inc Oligoribonucleotide derivatives and use thereof as antiviral drugs
JP2976436B2 (en) 1988-04-27 1999-11-10 味の素株式会社 The use of the new oligoribonucleotides derivatives and anti-viral agents
DE3907562A1 (en) 1989-03-09 1990-09-13 Bayer Ag Antisense oligonucleotides for the inhibition of transaktivatorzielsequenz (tar) and the synthesis of the transactivator (tat) of the HIV-1 and the use thereof
JPH04507402A (en) 1989-05-18 1992-12-24
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
DK0452457T3 (en) 1989-11-03 1998-03-02 Univ Vanderbilt A method for in vivo removal of the functional foreign genes
JP2693643B2 (en) 1991-10-15 1997-12-24 アイシス・ファーマシューティカルス・インコーポレーテッド Oligonucleotide having a chiral phosphorus bond
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
EP1223173B1 (en) 1992-07-23 2005-07-13 Isis Pharmaceuticals, Inc. Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
CA2078659A1 (en) 1990-03-21 1991-09-22 David J. Ecker Reagents and methods for modulating gene expression through rna mimicry
US5292875A (en) 1990-04-20 1994-03-08 Lynx Therapeutics, Inc. Method of synthesizing sulfurized oligonucleotide analogs
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
EP0542887B1 (en) 1990-08-09 1998-12-02 Genta Incorporated Psoralen conjugated methylphosphonate oligonucleotides as therapeutic agents for chronic myelogenous leukemia
EP0543938A4 (en) 1990-08-14 1993-11-10 Isis Pharmaceuticals, Inc. Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5646267A (en) 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
DE4110085A1 (en) 1991-03-27 1992-10-01 Boehringer Ingelheim Int New 2'O-alkyl-oligo-ribonucleotide(s) with 8-35 nucleotide units - useful as anti-sense oligo-nucleotide(s), primers and probes
WO1992017484A1 (en) 1991-03-27 1992-10-15 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides
WO1993007882A1 (en) 1991-10-25 1993-04-29 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of epstein-barr virus-associated diseases
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
US5606049A (en) 1992-06-03 1997-02-25 Genta Incorporated Method of preparing 2'-O-methyl cytidine monomers useful in oligomer synthesis
US6143881A (en) 1992-07-23 2000-11-07 University Of Massachusetts Worcester Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
WO1996018736A3 (en) 1994-12-13 1996-09-19 Ribozyme Pharm Inc Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
CA2152672A1 (en) 1993-01-06 1994-07-21 Paul Scott Miller Oligomers having improved stability at acid ph
CA2154578A1 (en) 1993-01-25 1994-08-04 Ekambar R. Kandimalla Oligonucleotide alkylphosphonates and alkylphosphonothioates
EP0695306A1 (en) 1993-04-19 1996-02-07 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
FR2705099B1 (en) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucleotide phosphorothioate triesters and method of preparation.
CA2166890A1 (en) 1993-07-19 1995-02-02 Nanibhushan Dattagupta Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
JPH0799976A (en) 1993-09-30 1995-04-18 Takeda Chem Ind Ltd Modified oligonucleotide
US5801235A (en) 1994-05-25 1998-09-01 Hybridon, Inc. Oligonucleotides with anti-cytomegalovirus activity
JPH10501224A (en) 1994-05-27 1998-02-03 ハイブリドン・インコーポレイテッド Use of an oligonucleotide phosphorothioate for complement depletion and hypotension
US5866699A (en) 1994-07-18 1999-02-02 Hybridon, Inc. Oligonucleotides with anti-MDR-1 gene activity
DE69521517T2 (en) 1994-09-07 2002-04-18 Hybridon Inc Prodrug oligonucleotides
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
JPH08154687A (en) 1994-12-12 1996-06-18 Yamanouchi Pharmaceut Co Ltd Anti-sense oligonucleotide and antiviral agent
CA2208528A1 (en) 1994-12-22 1996-06-27 Hybridon, Inc. Synthesis of stereospecific oligonucleotide phosphorothioates
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
GB9511720D0 (en) 1995-06-09 1995-08-02 Isis Innovation Oligonucleotide phosphorylation method and products
US20040234999A1 (en) 1996-04-02 2004-11-25 Farrar Gwenyth Jane Genetic suppression and replacement
EP1493818A3 (en) 1998-04-29 2006-02-15 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into ribozymes
EP1212416A2 (en) 1999-08-31 2002-06-12 Ribozyme Pharmaceuticals, Inc. Nucleic acid based modulators of gene expression
EP1073732A2 (en) 1998-04-29 2001-02-07 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into ribozymes
EP1626086A2 (en) 1998-04-20 2006-02-15 Ribozyme Pharmaceuticals, Inc. Double-stranded nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6344323B1 (en) 1998-09-16 2002-02-05 Vitagenix, Inc. Compositions and methods for inhibiting cox-2 expression and treating cox-2 associated disorders by using cox-2 antisense oligonucleotides
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JP2003510290A (en) 1999-09-27 2003-03-18 コーリー ファーマシューティカル グループ,インコーポレイテッド A method for immunostimulatory nucleic acid induced interferon
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
DE10013600A1 (en) 2000-03-18 2002-01-10 Aventis Res & Tech Gmbh & Co Reactive monomers for oligonucleotide and polynucleotide synthesis, modified oligonucleotides and polynucleotides and methods for their preparation
US6686461B1 (en) 2000-03-22 2004-02-03 Solulink Bioscience, Inc. Triphosphate oligonucleotide modification reagents and uses thereof
EP1247815A3 (en) 2001-03-25 2003-01-29 Exiqon A/S Modified oligonucleotides and uses thereof
US6900308B2 (en) 2001-07-16 2005-05-31 Isis Pharmaceuticals, Inc. α-modified nucleoside triphosphates
WO2003012052A3 (en) 2001-07-30 2005-03-31 Eric Wfw Alton Specific inhibition of gene expression by small double stranded rnas
FR2832154B1 (en) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotide inhibitors and their use for specifically repress a gene
US20030203868A1 (en) 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
RU2004129276A (en) 2002-02-28 2005-06-10 Астразенека Аб (Se) The 3-cyclic-5- (5-membered nitrogen-containing ring) -methyl-oxazolidinone, and their use as antibacterials
WO2003072757A9 (en) 2002-02-28 2004-10-21 Biota Inc Nucleotide mimics and their prodrugs
CA2479187A1 (en) 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
WO2003086280A3 (en) 2002-04-04 2004-11-25 Coley Pharm Gmbh Immunostimulatory g,u-containing oligoribonucleotides
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
KR20050026384A (en) 2002-04-26 2005-03-15 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 Expression systems for stem loop rna molecule having rnai effect
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
DE60328214D1 (en) 2002-08-12 2009-08-13 New England Biolabs Inc Methods and compositions for combination with gene-silencing
EP1546402A4 (en) 2002-09-04 2006-12-27 Johnson & Johnson Res Pty Ltd METHODS USING dsDNA TO MEDIATE RNA INTERFERENCE (RNAi)
EP1546182B1 (en) 2002-09-11 2011-01-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US20130130231A1 (en) 2002-11-26 2013-05-23 Isaac Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7696334B1 (en) 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
US20040265230A1 (en) 2003-01-06 2004-12-30 Martinez Robert Vincent Compositions and methods for diagnosing and treating colon cancers
WO2004074441A3 (en) 2003-02-19 2005-03-31 Kent Hunter Amplification or overexpression of mll septin-like fusion (msf) and septin9 and methods related thereto
CN1176937C (en) 2003-02-21 2004-11-24 复旦大学附属中山医院 Double-stranded RNA and use thereof
US20040261149A1 (en) 2003-02-24 2004-12-23 Fauquet Claude M. siRNA-mediated inhibition of gene expression in plant cells
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004080418A3 (en) 2003-03-12 2005-05-06 Parkash Gill Nucleic acid compounds for inhibiting angiogenesis and tumor growth
EP1606406B2 (en) 2003-03-21 2013-11-27 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
WO2004085623A3 (en) 2003-03-24 2005-12-22 Jeffrey C Mai A compact synthetic expression vector comprising double-stranded dna molecules and methods of use thereof
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US20050042641A1 (en) 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
CA2527907A1 (en) 2003-06-03 2004-12-09 Benitec Australia Limited Double-stranded hairpin rnas for rnai
JPWO2004108921A1 (en) 2003-06-06 2006-07-20 大日本住友製薬株式会社 Nucleic acid introduction method
CN102604957B (en) 2003-06-11 2015-10-07 艾德拉药物股份有限公司 Stabilized immunomodulatory oligonucleotide
FR2857013B1 (en) 2003-07-02 2005-09-30 Commissariat Energie Atomique Small RNAs specific INTERFERING alpha subunits, alpha prime and beta of the protein kinase CK2 and their applications
EP1747284A4 (en) 2004-02-06 2009-03-11 Wyeth Corp Diagnosis and therapeutics for cancer
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP1742958B1 (en) 2004-03-15 2017-05-17 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
EP1750775A2 (en) 2004-05-04 2007-02-14 Nastech Pharmaceutical Company, Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060035815A1 (en) 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
WO2007030619A3 (en) 2005-09-08 2007-10-04 Nastech Pharm Co Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US20070218079A1 (en) 2004-05-12 2007-09-20 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method to induce rnai in prokaryotic organisms
WO2006016574A1 (en) 2004-08-12 2006-02-16 Kumamoto University ANTINEOPLASTIC AGENT APPLYING RNAi
DE602004032245D1 (en) 2004-11-16 2011-05-26 Qiagen Gmbh Gene silencing (Gene silencing) by Sens hybrid DNA and antisense RNA constructs, coupled to a peptide to facilitate uptake into cells
JP4981681B2 (en) 2004-12-09 2012-07-25 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Workaround immune response to an immune response inducing composition and methods as well as oligonucleotide agent such as short interfering rna in a mammal
EP1838144B1 (en) 2005-01-07 2016-08-31 Oregon State University Method to trigger rna interference
WO2006078646A3 (en) 2005-01-18 2007-01-11 Gaetano T Caltagirone A class of supramolecular drug molecules and methods of identification and use thereof
US20060178334A1 (en) 2005-02-04 2006-08-10 City Of Hope Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon
US7998684B2 (en) 2005-02-07 2011-08-16 Takeda Pharmaceutical Company Limited Screening method for an agent for treatment of neurodegenerative disease
JP4645234B2 (en) 2005-03-03 2011-03-09 和光純薬工業株式会社 Crosslinking agents, crosslinking method using the same, method for regulating gene expression and gene function Methodology
EP2360249A1 (en) 2005-03-31 2011-08-24 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
CA2604441A1 (en) 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20070066521A1 (en) 2005-04-13 2007-03-22 Fauquet Claude M Short RNA-binding proteins
WO2006119643A1 (en) 2005-05-12 2006-11-16 Replicor Inc. Anti-ocular angiogenesis molecules and their uses
WO2006122409A1 (en) 2005-05-16 2006-11-23 Replicor Inc. Antimicrobial molecules and their uses
DK1888749T3 (en) 2005-06-01 2015-01-05 Polyplus Transfection Oligonucleotides for RNA interference as well as biological applications thereof
WO2006130949A1 (en) 2005-06-08 2006-12-14 Replicor Inc. Anti amyloid-related disease molecules and their uses
US8067573B2 (en) 2005-07-07 2011-11-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19 and methods of using same
CN101287835A (en) 2005-08-17 2008-10-15 株式会社百奥尼;株式会社三养社;韩国科学技术院 SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
EP1764107A1 (en) 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
WO2007031322A1 (en) 2005-09-14 2007-03-22 Gunther Hartmann Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
WO2007107304A3 (en) 2006-03-17 2008-06-12 Novosom Ag An efficient method for loading amphoteric liposomes with nucleic acid active substances
WO2007038788A3 (en) 2005-09-29 2007-10-25 Cleveland Clinic Foundation Small interfering rnas as non-specific drugs
EP2395012A3 (en) 2005-11-02 2012-03-14 Protiva Biotherapeutics Inc. Modified siRNA molecules and uses thereof
CA2991580A1 (en) 2007-05-01 2008-11-06 Santaris Pharma A/S Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
JP5066095B2 (en) 2005-11-17 2012-11-07 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム Regulation of gene expression by oligomers targeted to chromosome dna
DK1969125T3 (en) 2005-12-12 2012-07-23 Univ North Carolina Micro-RNAs that regulate the proliferation and differentiation of muscle cells
WO2007080457A3 (en) 2005-12-30 2008-01-03 Roussy Inst Gustave Use of inhibitors of scinderin and/or of ephrin-a1 for treating tumors
EP2021008B1 (en) 2006-04-07 2015-12-02 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
US20080091005A1 (en) 2006-07-20 2008-04-17 Visigen Biotechnologies, Inc. Modified nucleotides, methods for making and using same
US20100178272A1 (en) 2006-08-08 2010-07-15 Klinische Pharmakologie Structure and use of 5'phosphate oligonucleotides
CA2665403C (en) 2006-10-04 2015-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
EP1920775B1 (en) 2006-10-10 2012-12-19 Gunther Prof. Dr. Hartmann 5'Triphosphate oligonucleotide induces anti-viral response
WO2008045576A3 (en) 2006-10-12 2009-02-26 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
CN101190944A (en) 2006-12-01 2008-06-04 北京诺赛基因组研究中心有限公司;北京大学 Human cytokine and use thereof
CN101583715A (en) 2006-12-21 2009-11-18 因特拉迪格姆公司 Inhibitory polynucleotide compositions and methods for treating cancer
WO2008080091A3 (en) 2006-12-21 2008-08-21 Larry R Smith Activation of rig-i pathway
US7858772B2 (en) 2006-12-22 2010-12-28 Roche Molecular Systems, Inc. Compounds and methods for synthesis and purification of oligonucleotides
CA2675964C (en) 2007-01-16 2015-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008099396A1 (en) 2007-02-15 2008-08-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of h19-silencing nucleic acid agents for treating restenosis
US20110091974A1 (en) 2007-02-19 2011-04-21 Kyoto University Conductive Substrate and Method for Introducing Nucleic Acid
FR2913694B1 (en) 2007-03-13 2014-12-19 Malaysian Palm Oil Board Elements regulators of expression
CA2683063A1 (en) 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CN101088565A (en) 2007-04-17 2007-12-19 华东师范大学 Use of miRNA-34a
CN101289486B (en) * 2007-04-18 2012-05-30 上海吉凯基因化学技术有限公司 Process for synthesizing RNA monomer
WO2008134593A1 (en) 2007-04-25 2008-11-06 President And Fellows Of Harvard College Molecular circuits
EP2152889B1 (en) 2007-05-29 2017-03-15 Nature Technology Corp. Vectors and methods for genetic immunization
US20090123467A1 (en) 2007-07-31 2009-05-14 The Johns Hopkins University Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders
US8367815B2 (en) 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
WO2009038707A3 (en) 2007-09-17 2009-07-16 Ludwig Inst For Cancer Res Ltd Cancer-testis gene silencing agents and uses thereof
CN101970478A (en) 2007-10-11 2011-02-09 大学健康网络;多伦多儿童医院 Modulation of sirpalphalpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
US20100210710A1 (en) 2007-10-12 2010-08-19 Intradigm Corporation THERAPEUTIC siRNA MOLECULES FOR REDUCING VEGFR1 EXPRESSION IN VITRO AND IN VIVO
DE102007052114B4 (en) 2007-10-30 2011-01-05 T2Cure Gmbh A method of modulating the function, the growth or differentiation of a cell
JP2011502502A (en) 2007-11-05 2011-01-27 バルティック テクロノジー デヴェロプメント,リミテッド Use of an oligonucleotide containing the modified base in the hybridization of nucleic acids
CN101917846B (en) 2007-11-06 2014-06-25 圣诺制药公司 Multi-targeted RNAI therapeutics for scarless wound healing of skin
CA2704853C (en) 2007-11-06 2017-08-15 Eugen Uhlmann Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
US8575121B2 (en) 2007-11-12 2013-11-05 The United States of America as represented by the Secetary of the Department of Health and Human Services Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
EP2109690B9 (en) 2007-11-29 2012-10-24 MOLECULAR HEALTH GmbH Eph-b4 specific sirna for reducing epo-induced tumor cell growth during anemia treatment in cancer patients, tissue protective erythropoietin receptor (nepor) and methods of use.
GB0725321D0 (en) 2007-12-31 2008-02-06 Syntaxin Ltd Delivery vehicles
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
ES2553877T3 (en) 2008-05-21 2015-12-14 Rheinische Friedrich-Wilhelms-Universität Bonn 5'-triphosphate-oligonucleotide blunted and their uses
CA2635187A1 (en) 2008-06-05 2009-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University Oligonucleotide duplexes and uses thereof
WO2009151600A3 (en) 2008-06-10 2010-09-23 Tufts University Smad proteins control drosha-mediated mirna maturation
CN101632833B (en) 2008-07-25 2013-11-06 上海市计划生育科学研究所 Prostatic cancer related gene and application thereof
WO2011028218A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Process for triphosphate oligonucleotide synthesis
CA2735860A1 (en) 2008-09-02 2010-03-11 Alnylam Pharmaceuticals, Inc. Synthetic methods and derivatives of triphosphate oligonucleotides
WO2010042751A3 (en) 2008-10-08 2010-10-28 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042742A3 (en) 2008-10-08 2010-10-14 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042749A3 (en) 2008-10-08 2010-10-28 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042755A3 (en) 2008-10-08 2010-10-28 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
EP2363467B1 (en) 2008-10-23 2015-12-16 The University of Tokyo Method for inhibiting function of micro-rna
WO2010062502A1 (en) 2008-11-03 2010-06-03 University Of Utah Research Foundation Carriers for the delivery of nucleic acids to cells and methods of use thereof
CN102549166A (en) 2009-02-26 2012-07-04 俄亥俄州立大学研究基金会 Micrornas in never-smokers and related materials and methods
US8987222B2 (en) 2009-04-08 2015-03-24 University Of Massachusetts Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
WO2010120874A3 (en) 2009-04-14 2011-05-19 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
US20100323018A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Branched DNA/RNA monomers and uses thereof
EP2277508B1 (en) 2009-07-09 2012-04-25 Marina Biotech, Inc. Emulation of lipoprotein structures
WO2011008857A1 (en) 2009-07-14 2011-01-20 Northeastern University SiRNA PHOSPHOLIPID CONJUGATE
JP2013500265A (en) 2009-07-23 2013-01-07 ザ トラスティーズ オブ プリンストン ユニバーシティ mTOR kinase inhibitor used as antiviral agents
EP2327783A1 (en) 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
DE202009015670U1 (en) 2009-11-30 2011-04-14 Mcairlaid's Vliesstoffe Gmbh & Co. Kg Absorbent body to rest on wounds
US20110247091A1 (en) 2010-03-26 2011-10-06 The Governors Of The University Of Alberta Transgenic Cells and Chickens Expressing RIG-I
WO2011133559A3 (en) 2010-04-19 2012-08-09 University Of Georgia Research Foundation, Inc. Alpha tubulin acetyltransferase
WO2011140285A3 (en) 2010-05-04 2012-04-05 Sirnaomics, Inc. Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application
EP2385120A1 (en) 2010-05-04 2011-11-09 Justus-Liebig- Universitat Giessen Use of anti-miRNA antisense oligonucleotides for the treatment of pulmonary hypertension
CN101974529B (en) 2010-09-21 2013-04-03 南京大学(苏州)高新技术研究院 TGF-beta specific siRNA containing free triphosphoric acid group and application thereof
WO2012056441A1 (en) 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
WO2012056440A1 (en) 2010-10-28 2012-05-03 Nanodoc Ltd. COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
CN102475892A (en) 2010-11-22 2012-05-30 大连创达技术交易市场有限公司 Application of anti-sense miRNA (Ribonucleic Acid)-210 to preparation of anti-cancer drug
JP5836394B2 (en) 2010-12-30 2015-12-24 サムヤン バイオファーマシューティカルズ コーポレイション Anionic drug carriers, including cationic lipids and a method for producing
US8461224B2 (en) 2011-03-04 2013-06-11 National Health Research Institutes Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery
US20140212503A1 (en) 2011-03-17 2014-07-31 Hyukjin Lee Delivery system
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
JP2014520506A (en) 2011-07-04 2014-08-25 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイションCommonwealth Scientific And Industrial Research Organisation Nucleic acid complexes
EP2551354A1 (en) 2011-07-25 2013-01-30 Universität Heidelberg Functionalization of RNA oligonucleotides
US20130189367A1 (en) 2011-07-29 2013-07-25 University Of Washington Through Its Center For Commercialization Nanovectors for targeted gene silencing and cytotoxic effect in cancer cells
US9579394B2 (en) 2011-08-08 2017-02-28 Universitaet Regensburg Polyanion nanocomplexes for therapeutic applications
EP2765982A1 (en) 2011-10-11 2014-08-20 Hans Kosak Dimethyl sulfoxide as solvent for nucleic acids
WO2013053480A1 (en) 2011-10-11 2013-04-18 Secutech International Pte. Ltd. Composition for introducing nucleic acids into cells
US9631192B2 (en) 2011-11-17 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP)
EP2836219A1 (en) 2012-04-10 2015-02-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for the treatment of nonalcoholic steatohepatitis
US20130302252A1 (en) 2012-05-11 2013-11-14 University Of Washington Through Its Center For Commercialization Polyarginine-coated magnetic nanovector and methods of use thereof
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014124433A1 (en) 2013-02-11 2014-08-14 Oregon Health & Science University 5'-triphosphate oligoribonucleotides

Also Published As

Publication number Publication date Type
CN103492405B (en) 2017-02-15 grant
EP2691410A1 (en) 2014-02-05 application
DK2691410T3 (en) 2017-05-01 grant
CN103492405A (en) 2014-01-01 application
JP5981985B2 (en) 2016-08-31 grant
JP2017008071A (en) 2017-01-12 application
EP2691410B1 (en) 2017-03-22 grant
US20160298116A1 (en) 2016-10-13 application
US20140024819A1 (en) 2014-01-23 application
WO2012130886A1 (en) 2012-10-04 application
EP2508530A1 (en) 2012-10-10 application
ES2623002T3 (en) 2017-07-10 grant
JP2014514920A (en) 2014-06-26 application
CA2830980A1 (en) 2012-10-04 application
US9399658B2 (en) 2016-07-26 grant
EP3199538A1 (en) 2017-08-02 application
US9896689B2 (en) 2018-02-20 grant
CN106699829A (en) 2017-05-24 application

Similar Documents

Publication Publication Date Title
US5264562A (en) Oligonucleotide analogs with novel linkages
US7057031B2 (en) Nucleotide compositions comprising photocleavable markers and methods of preparation thereof
US6670461B1 (en) Oligonucleotide analogues
US5495009A (en) Oligonucleotide analogs containing thioformacetal linkages
Mansuri et al. Preparation of 1-(2, 3-dideoxy-. beta.-D-glycero-pent-2-enofuranosyl) thymine (d4T) and 2', 3'-dideoxyadenosine (ddA): general methods for the synthesis of 2', 3'-olefinic and 2', 3'-dideoxy nucleoside analogs active against HIV
US20040266996A1 (en) Methods of manufacture of 2'-deoxy-beta-L-nucleosides
US7572582B2 (en) Oligonucleotide analogues
US20030082807A1 (en) Xylo-LNA analogues
WO2000056748A1 (en) Xylo-lna analogues
WO2012138530A1 (en) 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
WO1999064431A2 (en) Purines and pyrimidines linked to a quencher
FR2607507A1 (en) New alpha -D-oligonucleotide derivatives, their preparation and their use.
WO2004106356A1 (en) Functionalized nucleotide derivatives
WO2003006475A2 (en) Method for preparation of lna phosphoramidites
WO2003008432A1 (en) Process for the preparation of alpha modified nucleoside triphosphates and compounds therefrom
WO1994029311A1 (en) Amino acid ester of nucleoside analogues
CN101600725A (en) Preparation of nucleosides ribofuranosyl pyrimidines
US8304529B2 (en) Dinucleotide MRNA cap analogs
JP2002521310A (en) Oligonucleotide analogs
Colacino et al. Simple and efficient routes for the preparation of isoxazolidinyl nucleosides containing cytosine and 5-methyl-cytosine as new potential anti-HIV drugs
WO2009143369A2 (en) Method of preparing nucleosides and analogs thereof without using chromatography
JP2003238586A (en) Method for producing highly stereoregular dinucleosidophosphorothioate
US20100273999A1 (en) Preparation of Nucleotide Oligomer
US8093367B2 (en) Preparation and isolation of 5′ capped mRNA
Umemoto et al. Oligoribonucleotide synthesis by the use of 1-(2-cyanoethoxy) ethyl (CEE) as a 2′-hydroxy protecting group

Legal Events

Date Code Title Description
AS Assignment

Owner name: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN, G

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LUDWIG, JANOS;GOLDECK, MARION;SPROAT, BRIAN;REEL/FRAME:039700/0850

Effective date: 20130920